Geno'X Veille — genox-veille.fr
Week of 17 November 2026
Literature review — Hereditary cancer genetics
8
curated articles
0
score ≥ 8/10
Key takeaways this week
- ►BRCA1 — Saturation genome editing of 4,113 previously unassayed variants: nearly half of HAP1 loss-of-function variants score neutrally in mammary cells, being hypomorphic with intermediate risk.
- ►POT1 — Across three biobanks (over 740,000 participants), moderately increased cancer risk (1.5- to 3.5-fold) from the mid-30s, without excess mortality.
- ►MSH2/EPCAM — Among 3,274 Lynch syndrome carriers, increased urothelial carcinoma risk (HR 4.43), the first cancer in one third of affected patients.
- ►PARP inhibitors — Cochrane meta-analysis of 24 trials: clear progression-free survival gain as maintenance, but reduced overall survival in platinum-resistant relapse (HR 1.36).
- ►NF1 — Consensus on nerve sheath tumours at risk of transformation: combined histological, molecular and imaging criteria, and MPNST risk stratification.
Weekly report in your inbox
Every Wednesday · Annotated selection · Free · Unsubscribe anytime
Articles of the week
8 articles of 8
Sort
BRCA1
PubMedSaturation genome editing of BRCA1 across cell types improves interpretation of variant pathogenicity
Hereditary breast and ovarian cancer predisposition (BRCA1)
7
Breast cancerFunctional SNV
Nat Genet 2026· NovRead
POT1
medRxivCancer risk and survival outcomes in germline POT1 variant carriers
Hereditary cancer predisposition (POT1)
7
Germline predispositionPenetrance updatePhenotypic expansion
medRxiv 2026· NovRead
MSH2, EPCAM
PubMedUrothelial Carcinoma in Lynch Syndrome: Clinical and Molecular Insights From a Large Multicenter Cohort
Lynch syndrome — urothelial carcinoma
7
Lynch syndromePenetrance update
JCO Precis Oncol 2026· NovRead
BRCA1/2
PubMedPoly (ADP-ribose) polymerase inhibitors (PARPi) for treating advanced epithelial ovarian cancer
Advanced epithelial ovarian cancer
7
PARP inhibitor
Cochrane Database Syst Rev 2026· NovRead
Breast cancer
PubMedDirect-to-implant or two-stage breast reconstruction in pathogenic mutations carriers after risk-reducing nipple-sparing mastectomy: A real-world multicenter cohort
Hereditary breast cancer predisposition — reconstruction after risk-reducing mastectomy
6
Breast cancerProphylactic surgery
J Plast Reconstr Aesthet Surg 2026· OctRead
Germline predisposition
bioRxivDeciphering the Dynamics of Leukemogenic Transformation from Clonal Hematopoiesis in Congenital Neutropenia
Congenital neutropenia and Shwachman-Diamond syndrome — progression to MDS/AML
6
Germline predisposition
bioRxiv 2026· NovRead
NF1
PubMedDefining and managing NF1-related peripheral nerve sheath tumors at risk for malignant transformation: Consensus from the Atypical Neurofibroma Symposium
Neurofibromatosis type 1 — peripheral nerve sheath tumours at risk of malignant transformation
5
New recommendation
Neuro Oncol 2026· NovRead
Lynch syndrome
PubMedLynch syndrome
Lynch syndrome
5
Lynch syndrome
Lancet 2026· NovRead
References and sources
- BRCA1 — Hereditary breast and ovarian cancer predisposition (BRCA1). Nat Genet 2026. PMID 43015421. Score 7/10. https://pubmed.ncbi.nlm.nih.gov/43015421/
- POT1 — Hereditary cancer predisposition (POT1). medRxiv 2026. doi:10.64898/2026.11.10.26367070. Score 7/10. https://www.medrxiv.org/content/10.64898/2026.11.10.26367070v1
- MSH2, EPCAM — Lynch syndrome — urothelial carcinoma. JCO Precis Oncol 2026. PMID 43024847. Score 7/10. https://pubmed.ncbi.nlm.nih.gov/43024847/
- BRCA1/2 — Advanced epithelial ovarian cancer. Cochrane Database Syst Rev 2026. PMID 43012369. Score 7/10. https://pubmed.ncbi.nlm.nih.gov/43012369/
- Hereditary breast cancer predisposition — reconstruction after risk-reducing mastectomy. J Plast Reconstr Aesthet Surg 2026. PMID 43019623. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/43019623/
- Congenital neutropenia and Shwachman-Diamond syndrome — progression to MDS/AML. bioRxiv 2026. doi:10.64898/2026.11.10.765578. Score 6/10. https://www.biorxiv.org/content/10.64898/2026.11.10.765578v1
- NF1 — Neurofibromatosis type 1 — peripheral nerve sheath tumours at risk of malignant transformation. Neuro Oncol 2026. PMID 43021633. Score 5/10. https://pubmed.ncbi.nlm.nih.gov/43021633/
- Lynch syndrome. Lancet 2026. PMID 43020098. Score 5/10. https://pubmed.ncbi.nlm.nih.gov/43020098/